Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other EventsItem 8.01.Other Events.
On December14, 2017, Axsome Therapeutics,Inc. (the “Company”) issued a press release announcing that it had entered into a research collaboration with Duke University to evaluate AXS-05 in a Phase 2 clinical trial in smokers attempting to quit. The planned study is a randomized, double-blind, controlled trial evaluating the impact of AXS-05 on smoking behavior, and will be conducted at the Duke Center for Smoking Cessation. Initiation of the trial is anticipated in the first quarter of 2018.
The full text of the press release is filed as Exhibit99.1 hereto and is incorporated herein by reference.
Item 8.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
Description |
99.1 |
Press release dated December14, 2017. |